Moving from gene discovery to clinical trials in Hutchinson-Gilford progeria syndrome
Hutchinson-Gilford progeria syndrome (HGPS) is a rare and fatal genetic disorder that results in accelerated atherosclerosis and signs and symptoms of rapid aging. The incidence has been estimated at approximately 1 in 4 million births. 1 Children with HGPS have failure to thrive, alopecia, thinning of skin, loss of body fat, headaches, atherosclerosis, cardiovascular disease, and stroke. Death occurs at an average age of 13 years and most commonly results from myocardial infarction or stroke.
The disease phenotype was first described in the late 1800s. 2, 3 In 2003, Eriksson et al. 4 discovered that HGPS is caused by a point mutation in the LMNA gene. The mutation causes abnormal mRNA transcription, leading to an abnormal variant of prelamin A protein named "progerin," which retains a farnesyl group that is normally removed. Accumulation of progerin causes the structure of the cell nucleus to take an abnormal shape and limits the cell's ability to divide. This discovery was groundbreaking because it offered insight into the mechanism of the disease and offered a possible target for treatment.
Less than 10 years after discovering the genetic cause of HGPS, a clinical trial was under way. Investigators used the positive results of mouse model studies 5 to launch an HGPS phase II trial of lonafarnib, a farnesyl transferase inhibitor that blocks the post-translational farnesylation of prelamin A. 6 The primary goal of the trial was to assess the medicine's effect on weight gain, but secondary outcomes were also evaluated. 6 In this issue of Neurology ® , Ullrich et al. 7 present the neurologic evaluations of the 26 trial participants. This seemingly small cohort represents 10%-13% of children with HGPS worldwide and 75% of the children in the International Progeria Registry. Among these children, 4 had a history of an overt stroke. One died of a stroke after 5 months on lonafarnib. The other 3 patients did not have new TIAs or strokes during the study period. The number of children who reported headaches dropped by more than 50%, from 15 to 7. The medical management for neurologic symptoms was shared between the physician investigator team at Boston Children's Hospital and the children's local neurologists. Nonstudy medicines were managed by each patient's local treating physician. Three children had anticoagulant agents used for stroke prophylaxis discontinued because their symptoms improved. For the first time, investigators offer encouraging data supporting an intervention to reduce the neurologic morbidity of HGPS.
Despite the positive findings from this phase II trial, there are limitations that temper the potential excitement. The results in this issue represent a retrospective, secondary analysis of the parent study. 6 Pretrial CNS imaging was not completed on all of the children. Stroke was a clinical diagnosis, and silent cerebral infarction was not assessed. Fifty percent of cerebral infarctions among children with HGPS were silent in a recent natural history study, 8 so imaging pre-and postlonafarnib would have been informative.
While the rapid evolution from gene discovery to human treatment in HGPS serves as a model for research in rare diseases, there are other potential benefits from the study of farnesyl transferase inhibitors and progerin. Progerin is produced at low levels in normal human cells. These levels increase with advancing age. There is a link between progressive telomere damage during cellular senescence and activation of progerin production. 9 Further elucidation of how progerin participates in the normal aging process may improve our understanding of a variety of age-dependent diseases.
Given the exciting trends in reduced neurologic morbidity during lonafarnib treatment of HGPS, more controlled and prospective evaluations of farnesyl transferase inhibitors with antiplatelet and anticoagulant agents and prospective imaging are needed. Despite the limitations of the retrospective analysis, these data are the first of their kind and offer hope. The partnership among the Progeria Research Foundation, physician scientists, federal and private funding, and the small community of families with this fatal disease have enabled relatively rapid progress in better understanding of both the mechanism of disease and the possibility of ameliorating the neurologic effects of HGPS. 
